LONDON, Ontario, Sept. 14, 2018 /PRNewswire/ — Trudell Medical International (TMI) is excited to announce its new High-Altitude Sleep Mask is now approved for sale in Austria, Belgium, France, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.
Venturing to high-altitude locations is increasingly common, and more and more people are being exposed to the effects of these hypoxic environments. TMI’s High-Altitude Sleep Mask is a new Class I medical device that provides a combination of mild exhalation resistance and CO₂ rebreathing. The result is a drug-free method of mitigating the effects of disrupted sleep at high-altitude by reducing high-altitude periodic breathing.¹ An added benefit of the TMI High-Altitude Sleep Mask is that rebreathing improves the heat and humidity of inhaled air in the typical cold, dry environment at altitude.
Equally exciting is that a recent pilot study shows that TMI’s High-Altitude Sleep Mask also reduces the severity of high-altitude headaches, the most common symptom of Acute Mountain Sickness (aka altitude sickness). ¹
For more information please visit www.altimatemask.com
¹ Based on unpublished results from a pilot study completed in March 2018
Jason Collins, Director Commercial Development, Trudell Medical International, JCollins@trudellmed.com, +1-519-455-7060 ext 2202